Wealdstone FC launches its 2020/21 Charity Partnership with MDUK
Wealdstone FC launches partnership with MDUK for 2020/21
Read more-
Statement: Cancellation of 2020 research Grant Round
06/05/2020Muscular Dystrophy UK regrets to announce that, due to the financial effect Covid-19 is having on our ability to generate income, we are cancelling the current Grant Round in 2020.
-
Impact of COVID-19 on Translarna Managed Access Agreement – an update
05/05/2020Read NICE statement about the impact of COVID-19 on access to Translarna.
-
The loss of Alexander Patrick CBE, DL
20/04/2020was with immense sadness that we have learnt of the passing of Alexander Patrick, CBE DL, an Honorary Life President of Muscular Dystrophy
-
Carmela’s brave 2.6 challenge
17/04/2020A six-year-old Devizes girl with a rare muscle wasting condition is planning to walk 26 laps of her personal therapy assault course, on 26 April.
-
Impact of COVID-19 on Spinraza Managed Access Agreement
07/04/2020Read NICE statement about the impact of COVID-19 on access to Spinraza.
-
Impact of COVID-19 on Translarna Managed Access Agreement
03/04/2020Read NICE statement about the impact of COVID-19 on access to Translarna.
-
SMA gene therapy Zolgensma given positive opinion
27/03/2020The SMA gene therapy Zolgensma has today been given a positive opinion by the European Medicines Agency (EMA).
-
Impact of new coronavirus laws
26/03/2020On 25 March new measures to deal with the coronavirus outbreak became law in the Coronavirus Act 2020.
-
COVID-19: an open letter to NICE
24/03/2020An open letter to NICE responding to its guidance on critical care for patients with COVID-19.
-
SMC decision for mexiletine
10/03/2020The Scottish Medicines Consortium has made the decision not to recommend mexiletine.